拜耳(Bayer)表示，其药物Nubeqa已获得美国食品药品管理局(Food and Drug Administration)的批准；该 药物用于治疗患有特定类型前列腺癌的患者。这家德国生命科学公司表示，此番批准是基于一项3期试 验的积极结果。相关试验结果显示，在接受Nubeqa联合另一种疗法治疗的患者中，发生影像学进展或 死亡的风险降低了46%。 ...

华夏时报（www.chinatimes.net.cn）记者 杨燕 北京报道 药企竞逐百亿美元市场 和睦家医疗北京区医疗副总监、大外科及泌尿外科主任朱刚教授对《华夏时报》记者表示，中国人的平均寿命从 解放前的39岁上升到现在的83岁以上，这也导致我们面临着很多老年疾病，前列腺癌就是其中之一，该肿瘤的高 发年龄是75岁左右，面对中国前列腺癌的快速增长，哪些癌该治，又怎么治，这些问题需要医生充分考虑清楚。 "例如一位85岁以上的老人被诊断出前列腺癌，治还是不治、怎么去治，国际共识认为，一个男性如果在85岁患上 早期前列腺癌，他将来死于前列腺癌的风险其实很低。因为早期前列腺癌的发展并没有那么快，这个时候建议病 人采取'观察等待'策略，国际上很多文献研究均支持这种做法。所以说得了前列腺癌，并不意味着一定要手术治 疗或药物治疗，应该根据病人的预期寿命来决定治疗方案。"朱刚强调。 值得庆幸的是，对于前列腺癌患者来说，治疗手段从传统的内分泌治疗、化疗，到新型抗雄药物、PARP抑制剂， 直至近期获批的放射性核素疗法，患者生存期已从过去的2—3年延长至5年以上。 国际制药巨头同样在这一领域展开激烈角逐。辉瑞与安斯泰来联合开发的恩 ...

当地时间5月18日，美国前总统小约瑟夫·拜登（Joseph R. Biden Jr.）的办公室发布声明，拜登因为泌尿系统症状就诊后， 被诊断出患有一种侵袭性前列腺 癌，癌症已经扩散到他的骨骼， 但似乎对激素敏感，他和家人正在与医生确定治疗方案。 拜登的前列腺癌格里森评分9分（最严重10分），分期为4期（最严重4期），发现即是晚期。早在1991年，前列腺特异性抗原（prostate specific antigen， PSA）血液检查已经被用于前列腺癌筛查。 以下文章来源于果壳 ，作者见文末 果壳 . 科学和技术，是我们和这个世界对话所用的语言。 作为今年1月才离任的前美国总统， 为什么他没能早点发现前列腺癌？ 文 ｜ 代天医 黎小球 编辑 ｜ odette 来源｜ 果壳（ID：Guokr42） 封面来源 ｜ 视觉中国 作为今年1月才离任的前美国总统，拜登每年都会接受例行体检，为什么他没能早点发现前列腺癌？ 8 2岁的拜登被确诊前列腺癌 ｜ 微博截图@央视新闻 美国是如何筛查前列腺癌的？ 根据拜登的年度体检报告结果分析，他可能近年没有接受常规PSA筛查。 拜登的情况，反映了美国公共卫生政策上对于前列腺癌筛查的态 ...

Summary of ProFound Medical (PROF) Update / Briefing April 29, 2025 Company Overview - ProFound Medical focuses on TULSA (Transurethral Ultrasound Ablation) technology for prostate cancer and benign prostatic hyperplasia (BPH) treatment [1][2] Key Industry Insights - TULSA is positioned as a mainstream treatment option for personalized prostate ablation, both malignant and benign [1] - The company has successfully enrolled in the CAPTAIN level one randomized control trial for prostate cancer, demonstrating strong clinical outcomes [1][4] Core Points and Arguments Prostate Cancer Treatment - The CAPTAIN trial has shown that TULSA PRO eliminates blood loss and overnight hospital stays, with TULSA patients averaging 0.29 days in the hospital compared to 1.24 days for robotic prostatectomy patients [10][11] - TULSA PRO patients reported statistically significant less pain and better overall health compared to those undergoing robotic prostatectomy [12][13] - The trial included 201 patients, with 194 treated or scheduled for treatment, indicating strong recruitment and interest in TULSA technology [5][6] BPH Treatment - ProFound Medical is introducing a new TULSA AI volume reduction module aimed at making TULSA a mainstream option for BPH patients [2][48] - The company estimates a total addressable market (TAM) of $5 billion for prostate cancer and BPH treatments, with a significant portion expected to be recurring revenue [48] Technological Advancements - The introduction of AI modules aims to improve clinical outcomes, reduce treatment time, and enhance workflow efficiency [50] - Features like the thermal boost module and contouring assistant are designed to ensure comprehensive treatment coverage and improve procedural efficiency [52][54] Patient Experience and Satisfaction - High patient satisfaction is indicated by an 88.5% recommendation rate for TULSA among patients, alongside a low regret score of 5.2 [15] - The TULSA procedure is noted for its precision, allowing for targeted treatment while minimizing damage to surrounding tissues, thus preserving erectile function and urinary control [80][81] Additional Important Insights - The CAPTAIN trial is the first of its kind to successfully randomize patients between TULSA and robotic prostatectomy, addressing previous challenges in trial design [5][8] - The company emphasizes the importance of patient demand in driving the adoption of surgical robots and TULSA technology [2][3] - ProFound Medical's focus on real-world outcomes and longitudinal tracking of patient data positions it favorably within the competitive landscape of prostate cancer treatments [44][65] Conclusion - ProFound Medical is at a pivotal point in establishing TULSA as a leading treatment option for both prostate cancer and BPH, supported by strong clinical data, technological advancements, and a focus on patient satisfaction and outcomes [1][4][48]

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations & Business Operations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive Vice President & Chief Commercial Officer Kevin Waters - Executive Vice President & Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of America Securities Patrick Wood - Morgan Stanley Ri ...